• 
WHEN
9, 8 and 10 
May 2024

REGISTRATION

Criteria for Registration

Registration for the 6th International Symposium on Immunobiologicals is free of charge and open to both Brazilians and foreigners.
To participate, it is a prerequisite to be a researcher, professional, student or professor in the area of immunobiologicals and related areas, from institutions of production, promotion, technological development of vaccines, biopharmaceuticals or reagents for diagnosis, or from the public health area.

The registration will give the participant access to the virtual platform of the event, with the right to participate in all lectures, visit the exhibition of posters and interact with other participants.

Participation in workshops, mini courses and webinars pre and post event will be made separately, with separate registration forms for each activity, only for participants registered in the ISI.

The organizers may refuse registration to any participant who is not in line with the symposium conduct, or who harms or endangers other participants or the event, at any time, according to their judgment.

Register now

7th ISI Schedule

Check the schedule for for the event

Expand All +

  • May 2nd



  • 08:30 – 09:30 Round table 1A – The challenge of Low Vaccination Coverage Situation in Brazil and Worldwide • Brazil – Ethel Maciel, SVS / Brazilian MoH* • Americas – Jarbas Barbosa, PAHO* • WHO – Samir Sodha, IVB/WHO* Chair: Akira Homma, Fiocruz* 9:30–10:00 Coffee break 10:00–11:00 Round table 1B – How to overcome the low vaccination Coverage Challenges? Brazilian field experiences • Creating connections with vulnerable groups – Oiapoque / Teatro Maiuhi, Elissandra Barros da Silva, Pet Indígena – Unifap* • Strategies to reconquest the high vaccination coverages in Paraíba State, Renata Nóbrega, Health Surveillance Unit from Paraíba* • For the Recovery of the High Vaccination Rates Project in Brazil through solidarity networks, Maria de Lourdes de Sousa Maia, PRCV Bio-Manguinhos* 11:00–11:30 Round table 1C – Challenges and perspectives for SUS to strengthen vaccination in Brazil • Primary health care agenda, Ricardo Gadelha de Abreu, Secretary of Primary Health Care, Ministry of Health* • Health surveillance agenda, Eder Gatti, Director, Department of Immunization and Preventable Diseases, Ministry of Health*

  • – Guided visit to the Museu da Vida and Fiocruz Castle – Guided visit to Bio-Manguinhos’ vaccine and biopharmaceuticals production site

  • 11:40 – 12:10 – Poster pitch
    VACCINATION COVERAGE IN BRAZIL • VAC-06 – Pertussis antibodies and vaccination coverage among healthcare professionals in Brazil is inadequate, Rita Soares Barbosa Cardona, USP • ORT-18- Human papillomavirus vaccination coverage in Brazilian North Region, 2013-2022, Mateus de Paula Von Glehn, EpiSUS • VAC-18 – Analysis of the possible factors associated with a low vaccination coverage among health Science undergraduates, Camila Costa dos Santos, UFF 12:20 – 12:50 – Poster pitch
    IMMUNE RESPONSE AND COVID-19 • VAC-09- Observational study of immunogenicity, effectiveness and reactogenicity in 6 months to 17 years age group of vaccines against COVID-19, Camila Amormino Corsini, Fiocruz/Minas IRR • IVD-06- New approaches in the detection of neutralizing antibodies using SARS-CoV-2 as a model, Caio Bidueira Denani, Fiocruz/Bio-Manguinhos • VAC-11 – Humoral immune response of allergic subjects vaccinated against COVID-19, Laura Alves Ribeiro Oliveira, Universidade Federal de Uberlândia
    Azul claro

  • Coral da Fiocruz ▪ Carlos Augusto Grabois Gadelha, Brazilian MoH ▪ Mario Santos Moreira, Fiocruz ▪ Maurício Zuma, Bio-Manguinhos ▪ Akira Homma, Coordenador Científico do 7th ISI*

  • Poster Poster Oral Presentation 1 (VAC) • VAC-03 – An alphavirus-derived replicon polyvalent RNA vaccine induces neutralizing antibodies in mice against omicron SARS-CoV-2 variant of concern, Vinicius Pinto Costa Rocha, SENAI CIMATEC
    Poster Oral Presentation 2 (VAC) • VAC-02 – Immunogenicity and protection evaluation of a live attenuated chimeric vaccine for zika virus in mice model, José Henrique Rezende Linhares, Fiocruz/Bio-Manguinhos

  • 14:40 – 15:10 – Poster pitch – VACCINOLOGY • VAC-08 – Integrating Next-Generation Phage Display and bioinformatics approaches for the screening of B-cell epitopes of different antigens using polyclonal sera, Alexsander de Moraes, USP – Faculdade de Medicina de Ribeirão Preto • VAC-07 – ntranasal Vaccinal strategy targeting mucosal surface for methicillin-resistant Staphylococcus aureus (MRSA) decolonization, Juliana Georg da Silva, Fiocruz/Bio-Manguinhos • VAC-13 – Development and comparison of potential DNA and mRNA vaccines for Dengue serotype 2, Sarah Aparecida Rodrigues Sérgio, CT Vacinas – UFMG

  • New technologies for accelerating vaccine development and new delivery methods • Adjuvants – Charles Lutsch, Sanofi* • Vaccine development in 100 days – Ann-Muriel Steff, CEPI* Chair: Sotiris Missailidis, Bio-Manguinhos

  • Vaccine hesitancy and the risk of polio re-emergence • Causes of vaccine hesitancy, data from the study on low vaccine coverage and adverse effects, José Cassio de Moraes* • Risk of Polio re-emergence in Brazil, Luiza Helena Falleiros*

  • May 3rd


  • Azul

  • Azul

  • – Guided visit to the Museu da Vida and Fiocruz Castle – Guided visit to Bio-Manguinhos’ vaccine and biopharmaceuticals production site

  • 11:40 – 12:10 – Poster pitch
    FROM INFECTIOUS DISEASES TO CANCER – NEW THERAPEUTIC APPROACHES
    • ORT-02 – Improvement CAR-T cell therapy with ultra-fast protocol and IL-15 membrane bound addition, Luiza de Macedo Abdo, INCa • ORT-03 – Evaluation of a betullinic acid nanosystem for cancer therapy, Natália Pereira da Rocha, Fiocruz • ORT-08 – Synthesis of polymeric nanoparticles of a high potency second generation isoniazid derivative aiming tuberculosis treatment via direct delivery to the lung, Frederico Silva Castelo Branco, Fiocruz/Farmanguinhos
    12:20 – 12:50 – Poster pitch
    BIOPHARMACEUTICALS AND CANCER
    • ORT-07 – Anti-her2 CAR-T cells evaluation in a ovarian tumor preclinical model, Emmanuel Arthur Albuquerque Aragao, INCa • BIO-04 – Structural modeling and design of scFv fragments from the antineoplastic antibody Brontictuzumab for enhanced binding to Notch1 NRR region, Aline de Oliveira Albuquerque, Fiocruz Ceará • BIO-08 – Regulation of the epigenetic machinery in pancreatic cancer, Ricardo Alberto Chiong Zevallos, USP

  • Biopharmaceuticals encoded by DNA and RNA • CART Cells to treat cardiac injuries using mRNA, Joel Rurik, University of Pensylvannia* • Next generation lipid nanoparticles technology for extrahepatic delivery of RNA molecules, Jayesh Kulkarn, NanoVation • Revolutionizing Antibody Discovery with Single-Cell Analysis, James Crowe, Vanderbilt Vaccine Center Chair: Patricia Neves, Bio-Manguinhos

  • Poster Oral Presentation 3 (BIO) • BIO-01 – Immune Checkpoint Blockade via PD-L1 Potentiates More CD28-Based than 4-1BB-Based Anti-Carbonic Anhydrase IX Chimeric Antigen Receptor T Cells, Najla Santos Pacheco de Campos, Universidade Federal do ABC Poster Oral Presentation 4 (MAN) • MAN-01 – Project For the Recovery of High Vaccination Coverage: innovation in structuring actions to promote vaccination at the local level, Isabel Cristina Alencar De Azevedo, Fiocruz/Bio-Manguinhos

  • 14:40 – 15:10 Poster pitch – NEW THERAPY APPROACHES • BIO-03 – Development and Characterization of Anti-VLA4 Monoclonal Antibody as a Potential Biopharmaceutical for the Treatment of Multiple Sclerosis, Vitória Fernandes de Castro, Fiocruz/Bio-Manguinhos • VAC-10 – Safety and immunogenicity of the anti-cocaine vaccine UFMG-VAC-V4N2 in a non-human primate model, Raissa Lima Gonçalves Pereira, UFMG • BIO-05 – CLEC5A expression can be triggered by spike glycoprotein and may be a potential target for COVID-19 therapy, Thiago Lazari Machado, Fiocruz/Bio-Manguinhos

  • Management of Biotech Development and Production in the 4th Industrial Revolution •First steps on the journey to the future of the productive sector, Igor Calvet, ABDI* •4th Industrial Revolution in Biotech industry, Marcio Freitas, Aché •Applications of 4.0 solutions in the pharmaceutical industry, Fabricio Costa, Deloitte* •4.0 platform for the new Bio-Manguinhos plant, Fernando Serva Cavalcanti Leite, Bio-Manguinhos* Chair: Luiz Alberto Lima*, Bio-Manguinhos

  • May 4th


  • Azul claro

  • Azul claro

  • Evolution of the development, regulation and use of biosimilars

  • 11:40 – 12:10 – Poster pitch
    TECHNOLOGICAL DEVELOPMENT AND INNOVATION TO CONTROL TO ENDEMIC INFECTIOUS DISEASES
    • IVD-02 – Kit NAT PLUS HIV/HBV/HCV/Malária Bio-Manguinhos: Innovation and technological upgrade for NAT, Daniele Ramos Rocha, Fiocruz/Bio-Manguinhos • ORT-04 – Evaluation of three antigens for the use in immunochromatographic rapid test for serological diagnosis of Human Visceral Leishmaniasis in Brazil, Allana Kelly Oliveira Dutra, Fiocruz/Bio-Manguinhos • IVD-08- Evaluation of Influenza A and SARS-CoV2 detection using RT-PCR by paired saliva and nasopharyngeal secretions samples, Pedro Henrique Cardoso, Fiocruz/Bio-Manguinhos 12:20 – 12:50 – Poster pitch
    VIRUSES – FROM RAPID TEST TO MULTIPLEX ASSAY
    • IVD-03 – A flow cytometry-based assay to measure neutralizing antibodies against SARS-CoV-2 virus, Veridiane Maria Pscheidt – UFCSPA • ORT-09 – Usefulness of rapid molecular assay to detect hepatitis C virus, Vanessa Duarte da Costa, Fiocruz/IOC • IVD-07 – Development of a multiplex RT-PCR molecular assay for Measles and Rubella viruses detection, Monica Barcellos Arruda, Fiocruz/Bio-Manguinhos

  • Cancer diagnosis and core demands • Diagnostics by sequencing and digital PCR. What can we expect? Ilana Zalcberg, INCa* • Real-time PCR and digital PCR applied to cancer diagnosis, John Young Lee, OPTOLANE Technologies Inc.* Chair: Patricia Alvarez da Silva Baptista, Bio-Manguinhos*

  • Poster Oral Presentation 5 (IVD) • IVD-01 – Detection of Plasmodium spp. in asymptomatic blood donors at Brazilian blood centers by the NAT PLUS HIV/HBV/HCV/MALARIA Bio-Manguinhos kit, Beatriz Vasconcello de Souza Barreto, Fiocruz/Bio-Manguinhos Poster Oral Presentation 6 (ORT) • ORT-01 – A high content image-based assay for detection and measurement of SARS-CoV-2 neutralizing antibodies, Vinicius Pinto Costa Rocha, SENAI CIMATEC

  • 14:40 – 15:10 – Poster pitch – INFECTIOUS DISEASES
    • ORT-05 – Evaluation of mutations in ABCB1 and ABCB11 genes by qPCR and their impact on the clinical evolution of hepatitis C, Leticia Bomfim Campos, Fiocruz/Instituto Oswaldo Cruz • ORT-06 – Thiourea Derivatives with Antimycobacterial and Anti-Inflammatory Activity as an Adjuvant Treatment Strategy for Severe Pulmonary Tuberculosis, Sanderson Dias Calixto, UENF • BIO-02 – Effect of lactoferrin as an immunomodulator and gene regulation of ferritin in different tissues of K18- hACE2 mice infected with SARS-CoV-2, Andrea Marques Vieira Da Silva – Fiocruz/Bio-Manguinhos

  • One Health and preparedness for the next pandemic • A. Alonso Aguirre, Colorado State University* • Mariangela Simão, Instituto Todos Pela Saúde* • Ann-Muriel Steff, CEPI* • Patricia Oliveira Pereira Tagliari, Anvisa* Chair: Akira Homma, Bio-Manguinhos

  • ▪ Poster Award Independent Committee Event close-up remarks Akira Homma, Bio-Manguinhos
    Cinza escuro

Speakers